Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesEfficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials
Annals of Oncology, 07/30/09
Regan MM et al. - In a study to investigate whether there is a subset of pts with castration-resistant prostate cancer (CRPC) for whom the efficacy of combination taxane–estramustine–carboplatin (TEC) chemotherapy may be greatest, it was determined that TEC chemotherapy has significant clinical activity in CRPC.
Methods- Individual patient data (n=310) were obtained from 7 trials using TEC chemotherapy.
- Prostate-specific antigen (PSA) response was defined as 50% post-therapy decline from baseline.
- Overall survival was defined from baseline to death from any cause.
- Logistic and Cox regression were used to investigate heterogeneity in outcome to TEC by pt and disease characteristics.
- Predicted survival probabilities were calculated from the Halabi Cancer and Leukemia Group B (CALGB) nomogram.
- Pooled PSA response proportion was 69%.
- There was no evidence of differential PSA response by disease characteristics.
- Established prognostic factors were associated with survival.
- Pooled 12-mo survival estimate of 79% was higher than the median 59% 12-mo nomogram-predicted survival.
Related Articles
Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer
BJU International, 11/02/09
Relevance Score: 88%
Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression
The Prostate, 10/07/09
Relevance Score: 82%
Comparative Analyses of Chromosome Alterations in Soft-Tissue Metastases within and across Patients with Castration-Resistant Prostate Cancer
Cancer Research, 10/06/09
Relevance Score: 81%
CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity
The Prostate, 11/02/09
Relevance Score: 80%
Palliative systemic therapy of castration-resistant prostate cancer
Der Urologe, 10/29/09
Relevance Score: 80%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy and Tolerability of Fesoterodine in Men With Overactive Bladder: A Pooled Analysis of 2 Phase III Studies
Urology, 12/07/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/07/09
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/07/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/07/09
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/07/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/07/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/07/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/07/09
Preoperative Criteria to Select Patients for Bilateral Nerve-sparing Robotic-assisted Radical Prostatectomy
The Journal of Sexual Medicine, 12/07/09
Article Search
Sponsor